Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2



Status:Recruiting
Conditions:Ocular, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Ophthalmology
Healthy:No
Age Range:18 - 80
Updated:4/21/2016
Start Date:October 2013
Contact:Robert J Mack, M.D.
Email:rjsmack@aol.com
Phone:847-755-9393

Use our guide to learn which trials are right for you!

Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2 in Eyes With Keratoconus or Ectasia

The primary objective of this study is to determine the effectiveness and safety of corneal
collagen cross-linking at irradiance levels of 9 and 18 mW/cm2.


General Inclusion Criteria

Prospective subjects must meet all of the following criteria to be eligible for
participation:

- 18 years of age or older

- Signed written informed consent

- Willingness and ability to comply with schedule for follow-up visits

- Contact lens removal prior to evaluation and treatment

Inclusion criteria for progressive keratoconus

Prospective subjects must meet two of the following criteria:

- Having a diagnosis of progressive keratoconus:

- An increase of ≥ 1.00 D in the steepest keratometry value

- An increase of ≥ 1.00 D in astigmatism manifest refraction

- A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective
manifest refraction

- Presence of central or inferior steepening on the Pentacam map.

- Axial topography consistent with keratoconus

- Steepest keratometry (Kmax) value ≥ 47.00 D

Inclusion criteria for ectasia

Prospective subjects must meet the following criteria:

- History of having undergone a keratorefractive procedure

- Meeting two of the following criteria

- Steepening by topography, either Pentacam or Humphrey

- Thinning of cornea

- Shift in the position of thinnest portion of cornea

- Change in refraction with increasing myopia

- Development of myopic astigmatism

- Development of irregular astigmatism

- Loss of best spectacle corrected acuity. 6.2 Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from this protocol:

- Eyes classified as either normal, atypical normal,

- Corneal pachymetry ≤ 350 microns at the thinnest point measured by Pentacam in the
eye to be treated

- A history of chemical injury or delayed epithelial healing in the eye to be treated.

- Pregnancy (including plan to become pregnant) or lactation during the course of the
study

- A known sensitivity to study medications

- Patients with nystagmus or any other condition that would prevent a steady gaze
during the treatment

- Inability to cooperate with diagnostic tests.

- Patients with a current condition that, in the investigator's opinion, would
interfere with or prolong epithelial healing.

- Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking
treatment.

- Patients who are unable to remain supine and tolerate a lid speculum for an extended
period of time.
We found this trial at
1
site
Hoffman Estates, Illinois 60169
Principal Investigator: Robert J Mack, M.D.
Phone: 847-755-9393
?
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials